NEW YORK, Oct. 9 (GenomeWeb News) - Massachusetts General Hospital and CytRx try to use RNAi technology to develop a drug to prevent and cure amyotrophic lateral sclerosis, the groups said today.
   
The agreement comes on the heels of an RNAi-based research program CytRx penned with the University of Massachusetts Medical School - from which the company recently acquired an exclusive licenses to the RNAi technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.